Figueira J, et al. - Over a 12-month period, the effectiveness of ranibizumab (RBZ) 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) was compared with PRP alone in the regression of the neovascularization (NV) area in subjects with high-risk proliferative diabetic retinopathy (HR-PDR). It was reported that the RBZ+PRP therapy was more effective for NV regression in HR-PDR participants, over 12 months, when compared to the PRP monotherapy.